Salt of Tetrahydroisoquinoline Derivative, Preparation Method, Medical Use
Summary
USPTO granted patent US12606551B2 to Zhejiang Hisun Pharmaceutical Co., Ltd. covering a salt form of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, its preparation method, and pharmaceutical compositions containing it. The patent classifies the compound as an angiotensin II type-2 receptor antagonist. Four claims were allowed.
“The present invention relates to a pharmaceutically acceptable salt of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, a preparation method therefor, a pharmaceutical composition comprising the pharmaceutically acceptable salt thereof, and the use thereof as a therapeutic agent, in particular as an angiotensin II type-2 receptor antagonist.”
What changed
USPTO granted patent US12606551B2 to Zhejiang Hisun Pharmaceutical Co., Ltd. covering a salt form of a tetrahydroisoquinoline derivative with four allowed claims. The patent includes the preparation method and pharmaceutical compositions for use as an angiotensin II type-2 receptor antagonist.\n\nPharmaceutical companies developing compounds in the angiotensin II receptor antagonist space should review this patent for potential overlap with their own compounds and consider whether licensing or design-around strategies are needed to avoid infringement.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Salt of tetrahydroisoquinoline derivative, preparation method therefor, and medical use thereof
Grant US12606551B2 Kind: B2 Apr 21, 2026
Assignee
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
Inventors
Yanghui Guo, Lichen Meng, Xiangui Huang, Weiwei Liao, Yongxiang Gong, Daiwang Xu, Taishan Hu, Lei Chen
Abstract
The present invention relates to a pharmaceutically acceptable salt of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, a preparation method therefor, a pharmaceutical composition comprising the pharmaceutically acceptable salt thereof, and the use thereof as a therapeutic agent, in particular as an angiotensin II type-2 receptor antagonist.
CPC Classifications
C07D 413/14
Filing Date
2021-06-25
Application No.
18012269
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.